Royalty Pharma plc - Ordinary Shares - Class A Forecast, price target & analysts
Royalty Pharma plc - Ordinary Shares - Class A Target price 2025 - Analyst rating & recommendation
Royalty Pharma plc - Ordinary Shares - Class A Classifications & Recommendation:
Royalty Pharma plc - Ordinary Shares - Class A Price Target
| Target Price | $43.35 |
| Price | $38.96 |
| Potential |
11.27%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Royalty Pharma plc - Ordinary Shares - Class A 2026 .
The average Royalty Pharma plc - Ordinary Shares - Class A target price is $43.35.
This is
11.27%
register free of charge
$56.70
45.53%
register free of charge
$35.02
10.12%
register free of charge
|
|
| A rating was issued by 15 analysts: 12 Analysts recommend Royalty Pharma plc - Ordinary Shares - Class A to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Royalty Pharma plc - Ordinary Shares - Class A stock has an average upside potential 2026 of
11.27%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.26 | 3.08 |
| 3.86% | 36.16% | |
| EBITDA Margin | 57.10% | 94.09% |
| 9.90% | 64.79% | |
| Net Margin | 37.95% | 86.09% |
| 21.27% | 126.86% |
12 Analysts have issued a sales forecast Royalty Pharma plc - Ordinary Shares - Class A 2025 . The average Royalty Pharma plc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
12 Royalty Pharma plc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2025. The average Royalty Pharma plc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.44 | 4.58 |
| 23.40% | 218.06% | |
| P/E | 8.50 | |
| EV/Sales | 9.61 |
12 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast for earnings per share. The average Royalty Pharma plc - Ordinary Shares - Class A EPS is
This results in the following potential growth metrics and future valuations:
Royalty Pharma plc - Ordinary Shares - Class A...
Current Royalty Pharma plc - Ordinary Shares - Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 25 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 30 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jul 22 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 10 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 25 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
